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Summary
 
An antagonist of human monocyte chemoattractant protein (MCP)-1, which consists of MCP-
1(9-76), had previously been characterized and shown to inhibit MCP-1 activity in vitro. To
test the hypothesis that, by inhibiting endogenous MCP-1, the antagonist has antiinflammatory
activity in vivo, we examined its effect in the MRL-
 
lpr
 
 mouse model of arthritis. This strain
spontaneously develops a chronic inflammatory arthritis that is similar to human rheumatoid
arthritis. Daily injection of the antagonist, MCP-1(9-76), prevented the onset of arthritis as
monitored by measuring joint swelling and by histopathological evaluation of the joints. In
contrast, controls treated with native MCP-1 had enhanced arthritis symptoms, indicating that
the inhibitory effect is specific to the antagonist. In experiments where the antagonist was given
only after the disease had already developed, there was a marked reduction in symptoms and
histopathology, although individuals varied in the magnitude of the response. The mechanism
of inhibition of disease is not known, although the results suggest that it could be more com-
plex than the competitive inhibition of ligand binding that is observed in vitro. The demon-
stration of the beneficial effects of an MCP-1 antagonist in arthritis suggests that chemokine re-
ceptor antagonists could have therapeutic application in inflammatory diseases.
 
M
 
onocyte chemoattractant protein (MCP
 
1
 
)-1 is a
chemoattractant cytokine (chemokine) (1) that pro-
motes the migration and activation of monocytes (2, 3). It
has been associated with several inflammatory diseases (4),
but a causal relationship has been difficult to prove. Mono-
cyte infiltrates are prominent in rheumatoid arthritis (RA)
and their products, such as cytokines that amplify the in-
flammatory response and enzymes that destroy connective
tissue (5), are readily detected in diseased joints. MCP-1 is
produced by both synovial cells and infiltrated monocytes
in RA (6–8). Thus, the inhibition of MCP-1 function
could control inflammation by preventing monocyte accu-
mulation in the joints.
To test the antiinflammatory effect of the MCP-1 antag-
onist, MCP-1(9-76) (9, 10), we chose a mouse model for
RA. Previous studies had shown that murine monocytes
respond to both human and mouse MCP-1 (11). The
MRL-
 
lpr
 
 mouse strain was chosen to test the antagonist be-
cause it has a genetic predisposition to arthritis with similar
characteristics to human RA including cell infiltration, pan-
nus formation, bone and cartilage breakdown, and the
presence of serum RF (12). The disease normally develops
towards the end of the animal’s life span (13); however, in-
jection with CFA initiates early onset and increases the se-
verity of arthritis, making the MRL-
 
lpr
 
 mouse a practical
experimental model for testing potential therapeutics (12).
 
Materials and Methods
 
The Proteins.
 
MCP-1, the antagonist, MCP-1(9-76), and the
control peptide, MCP-1Ala, were chemically synthesized and char-
acterized as described (9, 10). MCP-1Ala is an analogue of MCP-1
that had all the cysteines (residue numbers 11, 12, 36, and 52) re-
placed by alanines.
 
Arthritis Induction and Treatment.
 
Both male and female MRL-
 
lpr
 
mice were used at 13–14 wk of age and were bred at the Univer-
sity of British Columbia (Vancouver, Canada) from stock originally
obtained from the Jackson Labs. (Bar Harbor, ME). On Day 0 of
each experiment, all groups of mice were injected with CFA in-
tradermally into a thoracic and an inguinal site with 0.05 ml CFA
supplemented to 10 mg/ml with heat inactivated 
 
Mycobacterium
tuberculosis
 
 H37 RA (Difco, Detroit, MI) (12). Either immediately
or after a delay, depending on the experiment, mice were injected
either intravenously, intraperitoneally, daily or not at all, with the
appropriate antagonist or control protein. The chemokine analogue
treatment was continued for 30 d. The ankle width was determined
with a micrometer. For evaluation of the incidence of arthritis,
 
1
 
Abbreviations used in this paper:
 
 CCR, human CC chemokine receptor;
MCP, monocyte chemoattractant protein; RA, rheumatoid arthritis.
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the symptoms of impaired mobility, presence of erythema, or
swelling were scored as either 
 
1
 
 or 
 
2
 
. Statistical analysis of the in-
cidence was carried out with the one-tailed Fisher Exact test. For
quantifying swelling, ankle widths were measured with a mi-
crometer. The statistical comparison of paired sets of ankle width
measurements was carried out using the Student’s 
 
t
 
 test.
 
Histopathological Analysis.
 
At day 30 after CFA priming, the
hind paws were fixed in buffered formalin. After decalcification
in 10% formic acid for 48 h, the tissues were processed for paraf-
fin embedding. Serial sections of the tarso-metatarsal joints were cut
to a thickness of 5 mm and stained with hematoxylin and eosin.
Sections were examined by an individual without knowledge of the
experimental protocol. A minimum of 10 sections/joint were
assessed and scored to provide a semiquantitative measure of sub-
synovial inflammation (0, normal; 1, focal inflammatory infiltrates;
2, inflammatory infiltrate that dominated the cellular histology),
synovial hyperplasia (0, normal; 1, a continuous, minimum three-
layer thick, synovial lining seen in one joint; 2, minimum three-
layer thick, synovial lining detected in several joints), pannus
formation and cartilage erosion (0, normal; 1, pannus partially
covered cartilage surfaces without evident cartilage loss; 2, pannus
connected to evident cartilage loss), bone destruction (0, normal;
1, detectable destruction of bone by the pannus or osteoclast ac-
tivity; 2, the pannus or osteoclast activity had destroyed a signifi-
cant part of the bone), and finally, overall pathology was the
overall assessment derived by the summation of the values for
these criteria. Statistical analysis of the histopathology indices was
done using the Student’s 
 
t
 
 test.
 
Results
 
Receptor Interactions of the MCP-1 Antagonist.
 
The human
MCP-1(9-76) antagonist competed for binding of labeled
MCP-1 to receptors on human monocytic cells with a dis-
sociation constant (
 
K
 
d
 
) of 8.3 nM (9). In vitro it inhibited
MCP-1 (10 nM) with an ID
 
50
 
 of 70 nM (10). When tested
for competition binding of a number of chemokines, the
specificity of the antagonist was similar to that of native
MCP-1. It is likely that the inhibitory effects of the MCP-1
antagonist are due to its binding to the human CC chemokine
receptor (CCR)2 (14). The effects on mouse cells are proba-
bly due in part to blocking of the corresponding receptor,
murine CC chemokine receptor 2, which appears to be
similar to the human CCR2 in its specificity (15). Using a
murine myelomonocytic cell line, WEHI 274, the 
 
K
 
d
 
s of
human MCP-1 and the MCP-1 antagonist were 39 nM
and 58 nM, respectively. For the in vivo experiments, we
injected MCP-1(9-76) so that theoretically there was a 13-
fold (0.5 mg/kg) or a 54-fold (2.0 mg/kg) excess over the 
 
K
 
d
 
measured on mouse cells, estimated on the basis of an aver-
age exchangeable fluid volume of 2 ml per mouse. MCP-1
was at a 72-fold excess. The control MCP-1Ala analogue
had the same sequence as the antagonist except that all four
cysteines were replaced by alanines. This analogue lacks the
two essential disulfide bridges (Clark-Lewis, I., and J.-H.
Gong, unpublished data), did not bind to MCP-1 receptor,
and neither induced detectable chemotaxis, nor inhibited
MCP-1 chemotaxis (data not shown). Thus the control,
MCP-1Ala, was neither an agonist nor an antagonist.
 
MCP-1 Antagonist Inhibits the Onset of Arthritis Symp-
toms.
 
To test the effect of the antagonist on the onset of
disease, mice were primed with intradermal CFA on day 0.
When the MCP-1 antagonist was given intraperitoneally at
a dose of 2.0 mg/kg daily, it resulted in significant reduc-
tion of swelling of the ankle joint (Fig. 1 
 
a
 
). Controls that
received the same dose of a closely related but inactive ana-
logue, MCP-1Ala, developed similar swelling to that of
untreated controls, but showed a trend towards a delayed
onset. Although not significant, the effect was likely to be
due to the daily injection protocol. In subsequent experi-
ments, the controls were all injected with the control pep-
tide, MCP-1Ala. In a separate experiment where the an-
tagonist treatment was stopped at 15 d (Fig. 1 
 
b
 
), onset was
inhibited during the treatment interval, but swelling be-
came apparent by 20 d and rose to untreated control levels
by 24 d. Mice that received a fourfold lower intraperitoneal
dose of the antagonist did not have a significant reduction
in swelling, suggesting that for maximal effect, the concen-
tration of antagonist must be maintained at pharmacologi-
cal levels. Analysis of the sera for anti MCP-1 antibodies
Figure 1. The MCP-1 antagonist prevents the onset of the symptoms
of arthritis. The ankle widths for both hind legs of each animal were mea-
sured with a micrometer on the indicated days, and the results are pre-
sented as the mean change from the day 0 measurement, 6 SEM. *Values
are significantly different from the control MCP-1Ala analogue (P
,0.05). (a) MRL-lpr mice received CFA on day 0 and were injected in-
traperitoneally daily for 30 d with either MCP-1 antagonist, 2.0 mg/kg,
n 5 23, d; MCP-1 antagonist, 0.5 mg/kg, n 5 9, j; control MCP-1Ala
analogue, 2.0 mg/kg, n 5 10, h; or no further treatment, n 5 20, s. (b)
Mice were either injected intravenously daily for 15 d with MCP-1 an-
tagonist, 0.5 mg/kg, n 5 6, m; or received no further treatment, n 5 8,
s. Results shown are from one of two similar experiments. 
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showed that low titers (1:160) were present in both groups
(not shown). The production of anti–MCP-1 antibodies
was not considered a major factor in these studies.
 
Effects of the Antagonist on Joint Histopathology.
 
Histolog-
ical analysis of the ankle joints was performed at day 30 for
all the experiments described. Shown in Fig. 2 are photo-
micrographs taken from representative antagonist-treated
and control animals, from the experiment described in Fig.
1 
 
a
 
. The effects observed in control mice that were not
given MCP-1 antagonist included infiltration of mononu-
clear cells into the subsynovial tissue (Fig. 2 
 
a
 
), synovial hy-
perplasia, pannus formation (Fig. 2 
 
b
 
), and bone erosion
(Fig. 2 
 
c
 
). In contrast, mononuclear cell infiltration and
bone and cartilage pathology was absent in the MCP-1 an-
tagonist–treated example. Only minor thickening of the
subsynovium can be seen (Fig. 2 
 
d
 
). Analysis of the histo-
logical results (Fig. 3) for the experiment described in Fig-
ure 1 
 
a
 
, indicates that the group that received 2.0 mg/kg
antagonist had significant lower subsynovial inflammation,
synovial hyperplasia, pannus formation and cartilage ero-
sion, bone destruction, and overall histopathology. The his-
topathology results for the antagonist-treated group com-
pared favorably to age-matched animals that have not been
primed with CFA and have no disease symptoms (not shown).
Interestingly, compared to the controls, the group (Fig. 1 
 
a
 
)
that received 0.5 mg/kg had significantly lower overall his-
topathology (Fig. 3), even though joint swelling was not
significantly reduced. This suggests that the antagonist is
affecting cellular infiltration and pathology even in the
absence of an apparent effect on externally measurable
symptoms.
 
Native MCP-1 Enhances Arthritis.
 
To more completely
Figure 2. The effects of MCP-1 antagonist on the joint histopathology. Representative photomicrographs of histology from the experiment in Fig. 1
a are shown. For the control group: (a) marked subsynovial infiltration by mononuclear cells resembling rheumatoid nodule formation (320 objective);
(b) pannus formation and synovial hyperplasia (340) objective; (c) bone erosion (arrow; 320 objective). For the antagonist (2.0 mg/kg) -treated group: (d)
indicates some stromal thickening of the subsynovium, but absence of infiltrating cells or joint destruction (320 objective). as, articular surface; b, bone;
bm, bone marrow; bv, blood vessel; jc, joint cavity; mc, mononuclear cell infiltrate; p, pannus; sh, synovial hyperplasia; si, subsynovial inflammation; ss,
subsynovium. 
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describe this effect and to provide some insight into possi-
ble mechanisms, we examined the effect of full-length func-
tional MCP-1 in this model. Native MCP-1 treatment sig-
nificantly enhanced the disease, as indicated by the earlier
and higher incidence of disease (Fig. 4 
 
a
 
) and magnitude of
swelling (Fig. 4 
 
b
 
), compared to the inactive control pro-
tein. Thus, MCP-1 is causing hyperresponsiveness to arthri-
tis in the MRL-
 
lpr
 
 mouse, and is having the opposite effect
to the antagonist when both are compared to the inactive
control peptide. In contrast to the experiments described in
Figs. 3 and 6, for this experiment, histopathological analysis
was done 7 d after onset of symptoms and the time varied
from animal to animal. At this time point there was no sig-
nificant difference in the histopathology between the MCP-1
and control groups, although the trend was toward more
histopathology in the MCP-1 group, which is consistent
with the observed enhancement of swelling (not shown).
The MCP-1 antagonist significantly reduced inflammatory
infiltration, hyperplasia, bone destruction, and overall his-
topathology in this experiment.
 
MCP-1 Antagonist Inhibits Symptoms of Disease when Given
after Onset.
 
Although the experiments described so far
demonstrate that the MCP-1 antagonist is capable of pre-
venting the onset of arthritis, they do not show whether
the antagonist inhibits disease that is already evident. The
postonset situation is a much more stringent test of the abil-
ity of the antagonist to inhibit disease, as cell infiltration
and inflammatory events are already going on when the an-
tagonist treatment is started (12). Another reason to address
the postonset effects is that this more closely reflects the
clinical situation where symptoms are already apparent when
a patient presents with RA. To test the effects of the antag-
onist on existing disease, we primed the mice at day 0, but
then delayed treatment until after significant swelling was
apparent. The results for representative individuals from the
control peptide– (Fig. 5 
 
a
 
), and antagonist- (Fig. 5 
 
b
 
) treated
groups are shown. The individuals from the control group
generally had recurrent swelling after symptoms first be-
came apparent. This is typical of the disease in this model.
Individuals from the treated group showed an immediate
reduction of swelling and duration of inflammatory epi-
sodes. Some degree of relapse of the antagonist-treated ani-
mals was apparent at later time points, and the duration and
persistence of this was highly variable. Nevertheless, when
all the animals were taken into account (not shown), the
results indicated that the antagonist greatly reduced the symp-
toms.
MCP-1 antagonist treatment significantly reduced joint
histopathology by day 28. Thus, synovial hyperplasia, sub-
synovial inflammation, cartilage erosion, and overall histopa-
thology were significantly reduced in the antagonist treated
group (Fig. 6). This indicates that the external observation
of reduction of swelling in mice treated after disease onset
is reflected in the inflammatory disease in the joints, as
measured by histopathology.
 
Discussion
 
In this study, we have shown that a human MCP-1 re-
ceptor antagonist greatly reduces the symptoms and histo-
pathology of chronic arthritis in a disease model. Infiltra-
tion of the subsynovium by monocytes is prominent in
Figure 3. Summary of the effects of MCP-1 antagonist on joint histo-
pathology. Shown are the mean 6 the SEM of the scores, from the ex-
periment in Fig. 1 a, determined as described in Materials and Methods.
*Groups that were significantly different (P ,0.05) from the control
MCP-1Ala analogue for each histopathological parameter.
Figure 4. The effects of the functional MCP-1 agonist on disease inci-
dence and joint swelling. The mice were given CFA treatment at day 0
and divided into three groups. The groups received daily injection of 2
mg/kg of either native MCP-1 (1-76), n 5 24,  ; MCP-1 antagonist,
n 5 19, j; or the inactive control peptide, n 5 23, h. (a) The incidence
as percentage of mice that showed visible erythema or swelling on the days
indicated. (b) The change in the ankle widths (mean 6 SEM). *Signifi-
cantly different from controls (P ,0.05).135 Gong et al.
human RA, and thus, the diminished cellular infiltration
observed in these studies is probably due to inhibition of
endogenous MCP-1 receptors (see below). The results in-
dicate that the effect of the antagonist is reversible, because
when the antagonist treatment was stopped, the swelling
symptoms return. Moreover, antagonist treatment inhibited
the disease after symptoms were already apparent, suggest-
ing that there is turnover of cells that infiltrate the lesion
and that inhibition of further infiltration leads to reversal of
symptoms and pathology.
Native MCP-1 accelerated the onset and enhanced the
symptoms of joint inflammation. Predictions could have
been made, not only for the hyperresponsiveness that was
observed, but also for inhibition similar to that seen with
the antagonist. In vitro, MCP-1 results in migration only if
a gradient is formed and if at high concentrations, MCP-1
inhibits migration by collapsing the gradient (16). More-
over, both the agonist and the antagonist desensitize MCP-1
receptor signaling in vitro (4, 9). Nonresponsiveness has
also been reported in vivo for IL-8 (17). It is unlikely that
the enhancement we have observed in vivo with MCP-1 is
simply nonspecific, since the control protein, which is sim-
ilar chemically, did not cause this effect. Rather, it is more
likely that the systemic levels of MCP-1 in these mice are
insufficient to cause nonresponsiveness of the target cells to
MCP-1. Our interpretation for the enhancement of the on-
set and swelling is that the injected MCP-1 accumulates in
the tissues and causes activation of monocytes and other tar-
get cells, whereas the MCP-1 that remains in the vascular
compartment is eliminated rapidly. A gradient of MCP-1
from the ablumenal side (high) to the lumenal side of the
endothelium (low) could result in migration of responsive
cells from the blood into the tissues. Monocyte activation
could lead to some of the pathological effects observed
with MCP-1.
The results suggest that the in vivo action of the antago-
nist is dependent on its receptor binding and its inability to
cause activation. However, it cannot be directly proven
that the receptor blocking competition that occurs in vitro,
is also the mechanism in vivo. A case could be made for a
more complex mechanism. Physiologically, the CC chemo-
kine receptor system is redundant in that multiple CCRs,
which each bind several ligands, are coexpressed (18).
Thus, other chemokines and their receptors can induce
similar activities in vitro. Since only CCR2 receptor is in-
hibited by the MCP-1 antagonist, then the question arises:
why are we not seeing migration in response to other
chemokines, such as RANTES, that bind to CCR1, CCR3,
CCR4, and CCR5, but not CCR2 (18)? RANTES is also
produced in inflamed joints along with the MCP-1 (19).
The answer is not known. However we have found that a
RANTES antagonist, RANTES (9-68), also inhibits the
onset of arthritis in the model described here and, to a sim-
ilar extent, as the MCP-1 antagonist. The fact that two an-
tagonists that bind different receptors have similar effects
suggests that the independence of the receptor actions that
is observed in vitro is not directly translated to the in vivo
situation. It is possible that the long-term presence of an-
tagonist not only prevents cells from responding to chemo-
kine, but also prevents migration by another mechanism.
The antagonists do not stimulate detectable receptor signal-
ing, but likely promote receptor internalization, and there
Figure 6. The effect of postonset treatment with MCP-1 antagonist on
joint histopathology. Histopathological assessments of the experiment out-
lined in Fig. 5 were made 28 d after CFA priming. All the mice that de-
veloped significant swelling are included. The data is presented as for
Fig. 3. Shown are the mean 6 SEM of the assessment values for the indi-
cated parameters. *The antagonist and the controls are significantly differ-
ent, P ,0.05.
Figure 5. The effect of treatment with MCP-1 antagonist after disease
onset. Animals were injected with CFA once at day 0 and examined daily
for the visual appearance of erythema and swelling around the joints as
measured with a micrometer. 23 of 40 mice developed swelling at differ-
ent times, and they were injected daily with 2.0 mg/kg of either the
MCP-1 antagonist or the MCP-1Ala control, on the day indicated by the
arrows, until day 28. (a) The swelling measurements of three representa-
tive examples from the 13 controls (d, s, ).  (b) Three representative
examples from the 10 antagonist-treated mice (m, n, X).136 A Chemokine Antagonist Inhibits Arthritis in a Murine Model of RA
may be separate negative regulatory effects caused by re-
ceptor occupancy. Some of the possible mechanisms for
nonresponsiveness of chemokines have been reviewed (4).
Some that could apply to the MCP-1 antagonist are heter-
ologous desensitization of receptors, failure to stimulate ad-
hesion molecules (20), changes to the cytoskeleton (21), or
general interference of the formation of endogenous
chemokine gradients due to saturation of glycosaminogly-
can interaction sites (22). Another possibility is that chemokine
production is turned off by the presence of excess antago-
nist. This could occur if MCP-1–responsive cells have not
migrated, and therefore cannot amplify chemokine and cy-
tokine production. Further work will be necessary to de-
termine the in vivo mechanisms of chemokine antagonist
action. Nevertheless, our results indicate that the in vitro
patterns of receptor specificity and chemokine function do
not always correspond to in vivo effects.
Infiltrated monocytes are thought to be important in the
pathology of RA (5). Although MCP-1 primarily acts on
monocytes, it is also known to stimulate basophils (23) and
T lymphocytes (24), indicating that these cells could also be
stimulated by MCP-1 and/or be inhibited by the MCP-1
antagonist. Whatever target cells are important in this ar-
thritis model, the results suggest that blocking MCP-1 re-
ceptors breaks a critical link in the chain of inflammatory
events. Furthermore the antagonist prevents arthritis onset
and also alleviates existing disease, suggesting the potential
for MCP-1 antagonists or other cytokine inhibitors in the
therapy of the human disease. Antibody therapy represents
an alternative approach to inhibition of ligand function
(25). Beneficial effects in RA of antibodies that block tu-
mor necrosis factor–a activity have been described (26).
However, a potential disadvantage of the antibody ap-
proach in typical pathological situations is that targeting just
one ligand may not be effective. On the other hand, with
the antagonist approach, all the ligands for the receptor are
blocked. For example, the MCP-1 antagonist described
here blocks not only MCP-1 activity (9), but also MCP-2
(Gong, J.-H. and I. Clark-Lewis, unpublished observa-
tions) and MCP-3 (10).
Receptor antagonists that inhibit ligand binding and
function is a conventional pharmacological approach that
relies on competition between the antagonist and the natu-
ral agonist(s) for specific receptor binding sites. Antagonists
and agonists for seven transmembrane receptors, a class that
includes all the chemokine receptors, form the basis for
many widely used pharmaceuticals (27). Targeted receptors
include, for example, those for histamine, epinephrine, and
serotonin. Most of these antagonists are nonpeptide in nature
and are orally active, a major advantage for therapeutic use.
Nevertheless, nonpeptide antagonists of peptide ligands, in-
cluding neurokinins, cholecystokinin, and angiotensin, have
also been developed (27). Despite the fact that chemokines
are larger than these peptides, our results have indicated
that the major binding site on MCP-1 and other chemo-
kines is relatively small (9, 28), suggesting that nonpeptide
antagonists for chemokine receptors may be a future possi-
bility.
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